Related Experiment Video
Updated: Mar 31, 2026
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
Anticancer Activity and Molecular Docking Studies of Selected Benzoxazole Derivatives as Apoptosis Inducers in
Burcu Baba1, Çağla Zübeyde Köprü2, Ilkay Yildiz3
1Department of Medical Biochemistry, Faculty of Medicine, Yuksek Ihtisas University, Ankara, Türkiye.
Objective:
Non-small cell lung cancer (NSCLC), the most prevalent type of lung cancer, remains the leading cause of cancer-related deaths worldwide. Late-stage diagnosis and resistance to conventional treatments highlight the need for further research into its molecular mechanisms. This study aimed to evaluate the anticancer effects of several benzoxazole derivatives (2-(4-tert-butylphenyl)-5-nitrobenzoxazole (1a), 2-(4-tert-butylphenyl)-6-nitrobenzoxazole (1b), 2-(2,3-dimethylphenyl)-5-nitrobenzoxazole (2a), and 2-(2,3-dimethylphenyl)-6-nitrobenzoxazole (2b)) on the viability of A549 cells.
Materials And Methods:
Cell viability was assessed using the MTT assay. We also performed a molecular docking study to investigate the interactions between the benzoxazole derivatives and caspase-3, a key executioner caspase involved in apoptosis.
Results:
The benzoxazole derivatives coded 1a, 1b, 2a, and 2b exhibited anticancer activity against A549 cells, with half-maximal inhibitory concentration (IC50) values of 17.41±0.16, 20.50±0.08, 32.17±0.08, and 31.13±0.07 µM, respectively. Among the tested benzoxazoles, 1a and 1b showed activity comparable to cisplatin (IC50=19.65±0.09 µM). According to the docking results, all compounds demonstrated satisfactory docking scores ranging from -4.339 to -5.202 kcal/mol.
Conclusion:
Our results demonstrate that the benzoxazole derivatives 1a and 1b exhibit significant anticancer effects by inhibiting lung cancer cell proliferation at low concentrations, similar to cisplatin. The structure-activity relationship suggests that substitution of a phenyl group at the 2-position of the benzoxazole ring with a tert-butyl group at the para position enhances anticancer activity against A549 cells. This preliminary study indicates that these benzoxazole derivatives have promising potential as cytotoxic agents for the treatment of NSCLC.
Insights
New benzoxazole derivatives show promise as anticancer agents for non-small cell lung cancer (NSCLC). Compounds 1a and 1b demonstrated significant cytotoxic effects on lung cancer cells, comparable to cisplatin.
Area of Science:
- Medicinal Chemistry
- Oncology
- Molecular Biology
Background:
- Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality worldwide.
- Developing novel therapeutic strategies is crucial due to treatment resistance and late-stage diagnoses.
- Benzoxazole derivatives are being explored for their potential anticancer properties.
Purpose of the Study:
- To evaluate the in vitro anticancer effects of four novel benzoxazole derivatives against A549 lung cancer cells.
- To investigate the molecular interactions of these compounds with caspase-3 using molecular docking.
Main Methods:
- MTT assay was used to determine cell viability and IC50 values.
- Molecular docking studies were performed to assess binding affinity with caspase-3.
- Structure-activity relationships were analyzed based on chemical modifications.
Main Results:
- Benzoxazole derivatives 1a and 1b exhibited significant anticancer activity against A549 cells, with IC50 values of 17.41 µM and 20.50 µM, respectively.
- Compounds 1a and 1b showed comparable efficacy to cisplatin (IC50 = 19.65 µM).
- Molecular docking revealed satisfactory binding scores for all tested compounds, indicating potential interaction with caspase-3.
Conclusions:
- Benzoxazole derivatives 1a and 1b possess potent cytotoxic effects against NSCLC cells.
- The para-tert-butylphenyl substitution on the benzoxazole ring enhances anticancer activity.
- These compounds represent promising candidates for further development as NSCLC therapeutics.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:31The Intrinsic Apoptotic Pathway
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...